- Initiatives include restructuring and pipeline prioritization -
LOUISVILLE, Colo., Dec. 10 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) today announced an operational restructuring to align critical resources with strategic priorities. These priorities include identifying a partner for Replidyne's late-stage antibiotic, faropenem medoxomil (faropenem), advancing and expanding its infectious disease pipeline, and exploring additional corporate development opportunities.
The key elements of the Company's operating strategy going forward are
-- Corporate restructuring. To better align the organization with its
strategic and operations priorities, Replidyne has reduced headcount by
approximately 35 percent, primarily in the administrative, clinical,
regulatory, and commercial functions.
-- Pipeline programs. Replidyne will retain key research and development
expertise to progress its most promising preclinical programs,
including REP3123, its investigational antibacterial for the treatment
of C. difficile-associated disease (CDAD), and its DNA replication
inhibition program. As a result of prioritizing these preclinical
programs, Replidyne has suspended the development of topical antibiotic
REP8839 due to the additional investment required to optimize the
formulation and the niche market opportunity.
-- Development strategy for faropenem. Replidyne will continue its ongoing
placebo-controlled Phase III trial for faropenem in acute exacerbation
of chronic bronchitis (AECB). This clinical trial is approaching
50 percent enrollment and results are expected in 200
|SOURCE Replidyne, Inc.|
Copyright©2007 PR Newswire.
All rights reserved